CW Advisors LLC Has $1.52 Million Holdings in Cytokinetics, Incorporated $CYTK

CW Advisors LLC lifted its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 64.8% in the 2nd quarter, Holdings Channel reports. The fund owned 46,130 shares of the biopharmaceutical company’s stock after buying an additional 18,130 shares during the period. CW Advisors LLC’s holdings in Cytokinetics were worth $1,524,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cetera Investment Advisers raised its stake in Cytokinetics by 29.7% during the 1st quarter. Cetera Investment Advisers now owns 5,904 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 1,353 shares during the period. US Bancorp DE boosted its position in shares of Cytokinetics by 38.7% in the first quarter. US Bancorp DE now owns 2,410 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 672 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in shares of Cytokinetics by 38.9% during the first quarter. Ontario Teachers Pension Plan Board now owns 14,943 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 4,185 shares in the last quarter. Cynosure Group LLC raised its position in Cytokinetics by 34.3% during the first quarter. Cynosure Group LLC now owns 7,788 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 1,988 shares during the period. Finally, Covestor Ltd raised its position in Cytokinetics by 1,053.0% during the first quarter. Covestor Ltd now owns 1,914 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,748 shares during the period.

Insider Buying and Selling

In other Cytokinetics news, EVP Andrew Callos sold 52,486 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $65.95, for a total value of $3,461,451.70. Following the completion of the sale, the executive vice president owned 50,660 shares of the company’s stock, valued at $3,341,027. The trade was a 50.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John T. Henderson sold 8,750 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $63.90, for a total value of $559,125.00. Following the transaction, the director directly owned 74,578 shares in the company, valued at approximately $4,765,534.20. This represents a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 154,252 shares of company stock valued at $9,734,750 in the last three months. 3.40% of the stock is currently owned by corporate insiders.

Cytokinetics Stock Down 1.3%

NASDAQ CYTK opened at $65.67 on Monday. The stock has a market capitalization of $8.03 billion, a PE ratio of -10.44 and a beta of 0.58. Cytokinetics, Incorporated has a 12-month low of $29.31 and a 12-month high of $69.33. The company has a 50 day moving average price of $61.93 and a two-hundred day moving average price of $46.47.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The business had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. During the same quarter in the prior year, the business posted ($1.36) EPS. The firm’s revenue for the quarter was up 318.1% compared to the same quarter last year. As a group, equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on CYTK shares. Stifel Nicolaus lifted their target price on Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Evercore ISI upped their price objective on shares of Cytokinetics from $60.00 to $80.00 and gave the company an “outperform” rating in a research note on Wednesday, September 3rd. Royal Bank Of Canada increased their target price on shares of Cytokinetics from $82.00 to $87.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 11th. UBS Group restated a “neutral” rating and set a $61.00 price target on shares of Cytokinetics in a report on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a research note on Wednesday, October 8th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $79.29.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.